Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Pozzilli

Showing results (221-230 of 247) with videos related to

Pageof 25
Sort By:
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 3, 2009
The pharmacovigilance program on natalizumab in Italy: 2 years of experienceG Tedeschi, M P Amato, R D'Alessandro, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 19, 2025
Age-dependent response to initial highly effective treatment in relapsing multiple sclerosisEmilio Portaccio, Matteo Betti, Ermelinda De Meo, et al.
Neurology|April 19, 2022
Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood OnsetEmilio Portaccio, Angelo Bellinvia, Lorenzo Razzolini, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 16, 2021
Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worseningEmilio Portaccio, Laura Tudisco, Luisa Pastò, et al.
Neurology|May 29, 2026
Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term DisabilitySifat Sharmin, Izanne Roos, Pierre M Labauge, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 19, 2020
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factorsPietro Iaffaldano, Giuseppe Lucisano, Francesco Patti, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|December 31, 2013
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study groupAntonio Bertolotto, Marco Capobianco, Maria Pia Amato, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 29, 2023
Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS StudySerena Ruggieri, Luca Prosperini, Sarmad Al-Araji, et al.
Neurology and Therapy|September 19, 2025
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of FrailtyGina Ferrazzano, Roberta Fantozzi, Shalom Haggiag, et al.
Annals of Clinical and Translational Neurology|July 7, 2025
Early Intensive Versus Escalation Approach: Ten-Year Impact on Disability in Relapsing Multiple SclerosisPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.
Pageof 25

Showing results (221-230 of 247) with videos related to

Sort By:
Pageof 25
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 3, 2009
The pharmacovigilance program on natalizumab in Italy: 2 years of experienceG Tedeschi, M P Amato, R D'Alessandro, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 19, 2025
Age-dependent response to initial highly effective treatment in relapsing multiple sclerosisEmilio Portaccio, Matteo Betti, Ermelinda De Meo, et al.
Neurology|April 19, 2022
Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood OnsetEmilio Portaccio, Angelo Bellinvia, Lorenzo Razzolini, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 16, 2021
Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worseningEmilio Portaccio, Laura Tudisco, Luisa Pastò, et al.
Neurology|May 29, 2026
Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term DisabilitySifat Sharmin, Izanne Roos, Pierre M Labauge, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 19, 2020
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factorsPietro Iaffaldano, Giuseppe Lucisano, Francesco Patti, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|December 31, 2013
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study groupAntonio Bertolotto, Marco Capobianco, Maria Pia Amato, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 29, 2023
Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS StudySerena Ruggieri, Luca Prosperini, Sarmad Al-Araji, et al.
Neurology and Therapy|September 19, 2025
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of FrailtyGina Ferrazzano, Roberta Fantozzi, Shalom Haggiag, et al.
Annals of Clinical and Translational Neurology|July 7, 2025
Early Intensive Versus Escalation Approach: Ten-Year Impact on Disability in Relapsing Multiple SclerosisPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.
Pageof 25